Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Bell, Ottawa
John Bell, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20090144077 | METHOD AND SYSTEM FOR DETERMINING EXPOSURES PRESENTED BY AN ORCHESTRATED PROCESS - The present invention provides a system and method to dynamically identify, assemble, or otherwise simulate the availability of resources for an orchestrated service or application, thereby allowing for strategic changes in scheduling, purchasing, hiring, and the like to ensure that the resources needed to deliver the desired outcome during a particular time period are present. In particular, the system includes an orchestration module storing a plurality of resource parameters, correlating a predetermined criterion for one or more resources with an event, and simulating the event, where the simulation includes comparing the stored plurality of parameters with the predetermined criterion. The system further determines whether the stored plurality of parameters satisfy the predetermined criterion, and may store the determination for subsequent evaluation. | 06-04-2009 |
| 20110052539 | ONCOLYTIC RHABDOVIRUS - Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo. | 03-03-2011 |
John C. Bell, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20090317362 | USE OF MYXOMA VIRUS FOR THE THERAPEUTIC TREATMENT OF CANCER AND CHRONIC VIRAL INFECTION - The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer. | 12-24-2009 |
| 20100086522 | DISPARATE SUICIDE CARRIER CELLS FOR TUMOR TARGETING OF PROMISCUOUS ONCOLYTIC VIRUSES - The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject's immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval. | 04-08-2010 |
| 20100272687 | MUTANT VIRUSES AND USES THEREOF - The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells. | 10-28-2010 |
| 20110044937 | STAGED IMMUNE-RESPONSE MODULATION IN ONCOLYTIC THERAPY - The invention provides methods for treating tumours, such as solid tumours, in a host. The methods may involve infecting the tumour with an amount of one or more strains of oncolytic virus. The virus will generally be selected to be effective to cause a lytic infection of tumour cells within the tumour. In various embodiments, the host neutrophil response to the lytic infection may be modulated, so that during the course of the lytic infection, the host has an initial neutrophil response and a secondary neutrophil response, these two responses being different in some material respect. For example, the secondary neutrophil response may mediate a greater degree of apoptotic killing of tumour cells than does the initial neutrophil response. | 02-24-2011 |
| 20110206640 | ENGINEERED SYNERGISTIC ONCOLYTIC VIRAL SYMBIOSIS - In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host. | 08-25-2011 |
John Cameron Bell, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20110044952 | AMPLIFICATION OF CANCER-SPECIFIC ONCOLYTIC VIRAL INFECTION BY HISTONE DEACETYLASE INHIBITORS - The invention provides methods for treating cancer cells in a host by infecting the cancer cells with one or more strains of oncolytic virus, in conjunction with treating the host with an amount of an HDI that is effective to augment the cancer-cell-specific oncolytic infection. | 02-24-2011 |
Michael S.g. Bell, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20080312685 | System and Method for Moving and Stretching Plastic Tissue - A system and method of moving and stretching plastic tissue using dynamic force. An elastomeric driver is adjustably attachable to one or more anchors for securing the elastomer to the plastic tissue, providing a self adjusting system that is capable of exerting relatively constant tension over a certain distance. | 12-18-2008 |
Robert Bell, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20080302870 | COMPUTERIZED BIOMETRIC PASSENGER IDENTIFICATION SYSTEM AND METHOD - A system and method for passenger identity verification. The system has at least one check in system with a barcode reader and a biometric data collection device. When a passenger checks in, a barcode is placed on the passenger's boarding documents, the barcode is read, and biometric data is collected from the passenger. The system stores the data in a database of a server such that the barcode data is associated with the biometric data. The system further contains at least one checkpoint verification system with a bar code reader and a biometric data collection device. When the passenger arrives at the verification system, the barcode is read and biometric data is collected from the passenger. Biometric data is retrieved from the database using the bar code read by the verification system and the biometric data retrieved from the server is compared with the data collected by the verification system. | 12-11-2008 |
Shannon Bell, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20110280130 | Systems and Methods for Network Congestion Management Using Radio Access Network Congestion Indicators - Systems and methods for managing communications network congestion are provided. In an embodiment, the system includes a radio access network (RAN) interface configured to receive RAN congestion indicators, a congestion correlator module configured to correlate RAN congestion indicators to service congestion indicators, a database comprising a set of congestion based policy rules, a policy controller module configured to apply the congestion-based policy rules to achieve a policy decision, and a policy enforcement control point interface configured to transmit network control instructions to enforce the policy decisions. In another embodiment of the invention, a method is provided for managing communications network congestion, that includes receiving one or more radio access network (RAN) congestion indicators, correlating the one or more RAN congestion indicators to one or more service congestion indicators, applying a congestion-based policy rule based on service congestion indicators to generate a policy decision, and implementing the policy decision. | 11-17-2011 |